Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
NAVELBINE is an injectable small-molecule chemotherapy agent approved in 1994 for cancer treatment. The drug is administered via injection and represents a foundational oncology therapeutic in Pierre Fabre's portfolio. Specific indications and mechanism of action are not detailed in available data.
As a mature asset approaching loss of exclusivity, the NAVELBINE franchise likely operates with a lean, efficiency-focused commercial team managing competitive pressure (30% intensity) rather than expanding headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
Worked on NAVELBINE at Pierre Fabre? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With 271 linked jobs, NAVELBINE represents a significant employment hub at Pierre Fabre, spanning both R&D and Commercial functions. The product's mature status and approaching LOE suggest roles focused on operational efficiency, data analytics, and competitive strategy rather than launch or expansion activities.
271 open roles linked to this drug